Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Sanofi-Aventis Plans $1 Billion Generic Business To Support Managed Care

By Pharmaceutical Processing | October 25, 2004

WASHINGTON, DC (October 25, 2004) – Sanofi-Aventis plans to build a more than $1 billion generic business to help enhance its ability to contract with managed care, The Pink Sheet newsletter reported this week.

As the largest pharmaceutical company in Europe and the third largest worldwide, Sanofi-Aventis “has to make a strategic offer to health care providers that is not unilaterally based on high-priced innovative products,” Hanspeter Spek, Pharmaceutical Operations president, said during an October 21 earnings call.

The ability to contract across a broad product line is one of two reasons for building a generics presence, Spek said. The other is the recognition that all of Sanofi-Aventis’ current blockbuster brands will lose patent protection “during the next 10-15 years.”

Most brand name companies are once again experimenting with offering in-house generics, at least in cases where a blockbuster product foes off patent. However, Sanofi-Aventis appears to be the first major branded company to express a desire to offer a full-scale generic product line.

In the early 1990s, many brand companies pursued that strategy in response to the emergence of managed care. However, by the end of the decade, most had abandoned those efforts, according to The Pink Sheet, an authoritative prescription pharmaceutical and biotechnology newsletter (http://www.thepinksheet.com).

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE